Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 ibrutinib monotherapy in treatment-naive CLL/SLL (Japan)
jRCT2080223066Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Janssen Pharmaceutical. Started Jan 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on jRCT2080223066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223066.